Relevant outcomes for patients and caregivers are defined for each blood cancer, defined by the HARMONY Research Teams. HARMONY Research Projects are focusing on those particular outcomes that will expand our knowledge of Hematologic Malignancies and therapeutic approaches.
Click on links below and learn more about the challenge, partnership, project lead and envisioned impact. A summary of each project is included as well.
Public-private partnership for Big Data in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
